# Dupilumab Skin Barrier Function Study in Atopic Dermatitis

> **NCT04447417** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 52 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Dupilumab SAR231893

## Key facts

- **NCT ID:** NCT04447417
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-16
- **Primary completion:** 2021-06-17
- **Final completion:** 2021-06-17
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447417, "Dupilumab Skin Barrier Function Study in Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04447417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*